Pon1-KO Mouse
一般名
Pon1-KO
製品ID
S-KO-03736
背景情報
C57BL/6NCya
系統ID
KOCMP-18979-Pon1-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Pon1-KO Mouse（カタログ番号S-KO-03736）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Pon1-KO
系統ID
KOCMP-18979-Pon1-B6N-VA
遺伝子名
製品ID
S-KO-03736
遺伝子別名
Pon
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 6
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000002663
NCBIトランスクリプトID
NM_011134
ターゲット領域
Exon 3~7
有効領域の大きさ
~9.6 kb
遺伝子研究の概要
PON1, also known as paraoxonase 1, is a high-density lipoprotein (HDL) associated enzyme. It has antioxidant, anti-inflammatory, and anti-apoptotic roles, and its most important enzymatic activity in association with HDL is preventing low-density lipoprotein (LDL) oxidation, thus having anti-atherogenic activity [2,6,7]. PON1 is also involved in the detoxification of organophosphate insecticides [3,8].
PON1 gene polymorphisms have been associated with various diseases. A meta-analysis showed that the PON1 L55M polymorphism might increase the risk of cancer, especially breast cancer in some stratified analyses, and also increase cancer risk in Caucasian populations and in hospital-based studies [1]. Some SNPs of the PON1 gene are associated with stroke [2]. The PON1 192Q and 55L polymorphisms may increase the risk of organophosphate toxicity, especially among Caucasian populations [3]. The polymorphism of PON1 is associated with an increased risk of liver disease, and liver disease significantly reduces PON1 activity [4]. In idiopathic inflammatory myopathies (IIM), the arylesterase and lactonase activities of PON1 are significantly lower, and the PON1 QQ genotype associates with more favorable disease outcomes [5]. A meta-analysis in Chinese population suggested a weak association between the PON1 Q192R polymorphism and coronary heart disease risk [9].
In conclusion, PON1 is crucial for maintaining HDL functionality and protecting against oxidative stress and organophosphate toxicity. Its gene polymorphisms are associated with an increased risk of various diseases such as cancer, stroke, liver disease, and organophosphate toxicity, as well as influencing disease outcomes in IIM and coronary heart disease in specific populations. The study of PON1 gene polymorphisms helps to understand disease susceptibility and progression, providing potential targets for disease prevention and treatment.
References:
1. Hu, Peizeng, Ma, Yongchen, Zhang, Lingling, Ma, Sheng. 2016. PON1 L55M polymorphism might contribute to the risk of cancer. In Panminerva medica, 59, 107-113. doi:10.23736/S0031-0808.16.03212-2. https://pubmed.ncbi.nlm.nih.gov/27309259/
2. Tajbakhsh, Amir, Rezaee, Mehdi, Rivandi, Mahdi, Afzaljavan, Fahimeh, Pasdar, Alireza. 2017. Paraoxonase 1 (PON1) and stroke; the dilemma of genetic variation. In Clinical biochemistry, 50, 1298-1305. doi:10.1016/j.clinbiochem.2017.08.001. https://pubmed.ncbi.nlm.nih.gov/28779954/
3. You, Tian, Lv, Jingyu, Zhou, Liping. 2013. PON1 Q192R and L55M polymorphisms and organophosphate toxicity risk: a meta-analysis. In DNA and cell biology, 32, 252-9. doi:10.1089/dna.2012.1961. https://pubmed.ncbi.nlm.nih.gov/23590198/
4. Salari, Nader, Kazeminia, Mohsen, Mansouri, Kamran, Hosseinian-Far, Amin, Mohammadi, Masoud. 2021. The Activity and Polymorphism of the PON1 in Patients with Chronic Liver Disease: a Systematic Review and Meta-analysis. In Journal of gastrointestinal cancer, 53, 745-755. doi:10.1007/s12029-021-00699-7. https://pubmed.ncbi.nlm.nih.gov/34467517/
5. Bae, Sangmee Sharon, Shahbazian, Ani, Wang, Jennifer, Reddy, Srinivasa T, Charles-Schoeman, Christina. . Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies. In Rheumatology (Oxford, England), 61, 2512-2523. doi:10.1093/rheumatology/keab795. https://pubmed.ncbi.nlm.nih.gov/34698804/
6. Mahrooz, Abdolkarim. 2024. Pleiotropic functions and clinical importance of circulating HDL-PON1 complex. In Advances in clinical chemistry, 121, 132-171. doi:10.1016/bs.acc.2024.04.003. https://pubmed.ncbi.nlm.nih.gov/38797541/
7. Marsillach, Judit, Richter, Rebecca J, Costa, Lucio G, Furlong, Clement E. . Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates. In Current protocols, 1, e25. doi:10.1002/cpz1.25. https://pubmed.ncbi.nlm.nih.gov/33484495/
8. Costa, Lucio G, Giordano, Gennaro, Cole, Toby B, Marsillach, Judit, Furlong, Clement E. 2012. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. In Toxicology, 307, 115-22. doi:10.1016/j.tox.2012.07.011. https://pubmed.ncbi.nlm.nih.gov/22884923/
9. Zhang, Zhen, Ou, Junke, Cai, Peiling, Niu, Bei, Li, Jian. . Association between the PON1 Q192R polymorphism and coronary heart disease in Chinese: A meta-analysis. In Medicine, 97, e11151. doi:10.1097/MD.0000000000011151. https://pubmed.ncbi.nlm.nih.gov/29952962/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。